Luteolin for Stage IV Cancer
Also known as: 3',4',5,7-Tetrahydroxyflavone
Luteolin inhibits multiple cancer kinases and modulates tumor immunity through mast cell and NF-κB modulation.
Mechanism of Action
Luteolin inhibits CK2, CDK2, and topoisomerase II, induces apoptosis through p53 stabilization, and modulates tumor-associated mast cells that promote angiogenesis and immunosuppression. It also inhibits epithelial-mesenchymal transition.
General mechanism: Flavone. Mast cell stabilizer, NF-κB/NLRP3 inhibitor, CK2 inhibitor, BACE1 inhibitor, Nrf2 activator. Crosses BBB.
Current Evidence
Preclinical evidence for multiple cancer types. Anti-metastatic effects through EMT inhibition. Phase I studies limited.
Clinical Status: Preclinical. Available as supplement.
Safety Profile
Very safe. Present in celery, peppers, parsley. Well-tolerated as supplement. No significant side effects.
Key Research Questions
- Can luteolin reduce tumor-associated mast cell-driven immunosuppression?
- Does luteolin inhibit metastasis through EMT modulation?